Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin

30 Oct 2014

Abstract excerpt

We previously reported high expression of RAD51 and increased homologous recombination (HR) rates in multiple myeloma (MM) cells, and showed that genomic instability and disease progression are commensurate with HR levels. Moreover, high RAD51 expression in vivo is associated with chemoresistance and poor patient survival. Doxorubicin (DOX) is one of the most widely used drug treatments in MM chemotherapy. DOX is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25401086
DOI: 10.3389/fonc.2014.00289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to DoxorubicinPMID 25401086Read ↗

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadSemantic proximity Read ↗

RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid TumorsSemantic proximity Read ↗

A Small Molecule Inhibitor of Human RAD51 Potentiates Breast Cancer Cell Killing by Therapeutic Agents in Mouse XenograftsSemantic proximity Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.Semantic proximity Read ↗

New RAD51 Inhibitors to Target Homologous Recombination in Human CellsSemantic proximity Read ↗

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell SurvivalSemantic proximity Read ↗

Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance ChemosensitivitySemantic proximity Read ↗

Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significanceSemantic proximity Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics.Semantic proximity Read ↗

Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.